Catalog No.
Product Name
Application
Product Information
Citations
-
HBV Inhibitor
Tiviciclovir is a guanosine analog that acts as a selective inhibitor of hepatitis B virus (HBV). Its primary mechanism involves interfering with viral replication, making it a valuable tool in the study of HBV-associated diseases. This compound is primarily utilized in research focused on antiviral therapy and the development of treatments for chronic hepatitis B infections. -
HBV Inhibitor
2'-Deoxy-L-adenosine is a potent inhibitor of hepatitis B virus (HBV) replication, targeting the viral polymerase with high specificity and selectivity. This compound functions as a synthon for modified oligodeoxyribonucleotides, making it a valuable tool for research focused on HBV and related hepatotropic viruses, including woodchuck and duck hepatitis viruses. Its ability to interfere with viral replication positions it as a significant reagent in studies aimed at understanding and developing therapies for HBV infections. -
Reverse Transcriptase Inhibitor
Lamivudine triphosphate TEA is a potent reverse transcriptase inhibitor that functions by terminating the elongation of viral nucleic acids. It effectively inhibits the reverse transcriptase of HIV and HBV, thereby obstructing viral replication. Additionally, Lamivudine triphosphate TEA targets the RNA-dependent RNA polymerase (RdRp) of the NS5B subunit in HCV, and can be incorporated into the RNA by the RdRp of SARS-CoV-2, interrupting the synthesis and leading to a decrease in mutations in the viral genome. This makes it a critical reagent for research in antiviral therapies and viral replication studies. -
Anti-HBV Agent
Glycosmisic acid is a natural compound that exhibits anti-hepatitis B virus (HBV) activity. It is employed in research related to viral infections, particularly in studies aimed at understanding and developing therapeutic strategies against HBV. This compound may also serve as a valuable tool for investigating the molecular mechanisms underlying HBV pathogenesis. -
HBV Inhibitor
Besifovir Dipivoxil maleate is a potent HBV inhibitor acting as an oral proagent of LB80317. It demonstrates significant efficacy in suppressing hepatitis B virus (HBV) DNA in both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patient populations. This compound is valuable for research into therapeutic strategies for managing chronic hepatitis B infections. -
HBV Capsid Assembly Modulator
SHR5133 is a potent HBV capsid assembly modulator that functions through the inhibition of hepatitis B virus (HBV) capsid assembly. Demonstrating an EC50 of 26.6 nM, SHR5133 effectively reduces HBV DNA levels. This compound is primarily utilized in research applications focused on HBV infection and therapeutic development. -
Anti-HBV Agent
Firzacorvir is a cyclic sulfamide compound that targets and modulates the hepatitis B virus (HBV) core protein. It exhibits significant anti-HBV activity with an EC50 of less than 1 μM. This reagent is essential for research applications focused on the treatment and management of HBV infections. -
Reverse Transcriptase Inhibitor
Lamivudine salicylate is a nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against HIV reverse transcriptase 1/2 and hepatitis B virus reverse transcriptase. Its oral bioavailability and ability to penetrate the central nervous system make it a valuable compound for anti-viral research. Lamivudine salicylate is widely utilized in studies focused on the treatment and management of HIV and hepatitis B infections. -
HBV Inhibitor
HBV-IN-46 is a potent inhibitor of Hepatitis B virus (HBV) S-antigen, demonstrating an EC50 value of 2.6 nM. This active metabolite is valuable for research related to HBV infection and presents a promising tool in the development of antiviral therapies targeting HBV. Its specificity and efficacy make it a useful reagent for studying viral replication and host-pathogen interactions in HBV-related research. -
HBV Modulator
HBV-IN-17 is a potent modulator of Hepatitis B Virus (HBV) capsid assembly, exhibiting an effective concentration (EC50) of 511 nM. This compound targets the viral capsid formation, disrupting the assembly process critical for HBV replication. It is useful in research applications focused on understanding HBV biology and developing potential therapeutics for HBV infection. -
HBV Capsid Assembly Modulator
BA38017 is a potent modulator of HBV core protein assembly, specifically targeting the hepatitis B virus (HBV) replication process. It demonstrates significant inhibitory activity with an EC50 of 0.20 μM, making it a valuable tool for studying HBV biology. This compound is essential for research applications focused on understanding HBV pathogenesis and evaluating potential therapeutic strategies against hepatitis B infection. -
HBV Inhibitor
HBV-IN-43 is a potent inhibitor of Hepatitis B Virus (HBV) replication. This compound demonstrates strong antiviral activity by targeting key viral processes, making it a valuable tool for research into HBV pathogenesis and therapeutic strategies. Its efficacy in inhibiting HBV provides insights into the development of antiviral therapies for Hepatitis B infection. -
Anti-HBV/HDV Agent
Elebsiran is a small interfering RNA (siRNA) that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. This agent significantly reduces HBV surface antigen (HBsAg) levels and viral load, indicating its potent antiviral activity. By binding to the asialoglycoprotein receptor (ASGPR) on liver cells via the GalNAc ligand, Elebsiran enables liver-targeted delivery while ensuring improved liver safety. This reagent is valuable for research focused on chronic HBV and HDV infections. -
HBV Fragment
HBV Seq1 aa:63-71 is a peptide fragment derived from the hepatitis B virus. This specific sequence is instrumental in studying viral protein structure and function, particularly in the context of immune response and vaccine development. Its application extends to investigations of HBV pathogenesis and potential therapeutic targets within the viral lifecycle. -
HBV
Ozisiran is a small interfering RNA (siRNA) that targets hepatitis B virus (HBV) RNA transcripts, leading to a reduction in viral load. This compound exhibits potent antiviral activity, making it a valuable tool for research into HBV pathogenesis and therapeutic interventions. Its application in studies of antiviral mechanisms can enhance understanding of HBV infection and facilitate the development of novel antiviral strategies. -
HBV Inhibitor
HBV-IN-41 is a potent inhibitor of the Hepatitis B Virus (HBV), exhibiting a remarkable EC50 of 0.027 μM. This orally active compound effectively targets viral replication, making it a valuable tool for research into HBV pathogenesis and potential therapeutic interventions. Its efficacy positions it as a significant reagent for studies aimed at developing new antiviral strategies against HBV. -
Anti-HBV Agent
Z060228 is a capsid-targeting anti-HBV agent that inhibits hepatitis B virus (HBV) DNA replication. It demonstrates significant antiviral activity in HepG2.2.15 cell supernatants, making it a valuable tool for HBV research. This compound is useful for studies focused on HBV replication mechanisms and the development of therapeutic strategies against hepatitis B virus infections. -
HBV Inhibitor
Valtorcitabine dihydrochloride is a prodrug of L-deoxycytidine with targeted activity against hepatitis B virus (HBV). It functions as an HBV inhibitor, effectively reducing viral replication and promoting antiviral responses. This compound is primarily utilized in research focusing on HBV infection and the development of therapeutic strategies for managing viral hepatitis. -
Anti-HBV Agent
LPRP-Et-97543 is a potent anti-HBV agent targeting multiple HBV promoters. It effectively reduces Core, S, and preS promoter activities while exhibiting no impact on the X promoter. This compound is suitable for research into both acute and chronic hepatitis B virus infections, making it a valuable tool for studying viral pathogenesis and potential therapeutic interventions. -
Anti-HBV Agent
Junceellolide C is a transcription inhibitor targeting cccDNA, effectively impeding HBV DNA replication. It demonstrates significant reductions in supernatant HBV RNA, with EC50 values of 5.19 μM and 3.52 μM in HepAD38 cells. This compound is recognized for its potent anti-HBV activity, making it a valuable tool for research into therapeutic strategies against hepatitis B virus infections. -
HBV Inhibitor
AT-61 is a non-nucleoside inhibitor that targets Hepatitis B virus (HBV) replication. It disrupts the formation of the capsid necessary for pre-genomic RNA, leading to the generation of empty capsids. This compound demonstrates efficacy against drug-resistant HBV mutant strains and is suitable for research focused on HBV infection mechanisms and therapeutic strategies. -
HBV Inhibitor
Xalnesiran is a small interfering RNA (siRNA) specifically designed to inhibit hepatitis B virus (HBV) replication. By targeting and degrading HBV RNA, it plays a crucial role in reducing viral load and the associated liver pathology. Xalnesiran is valuable for research applications focused on chronic hepatitis B treatment strategies and the investigation of RNA interference mechanisms in viral infections. -
HBV Inhibitor
Glaziovine is an antiviral compound derived from Hypserpa nitida, specifically targeting hepatitis B virus (HBV). It demonstrates potent inhibitory activity against HBV, effectively suppressing the secretion of hepatitis B virus surface antigen (HBsAg) in Hep G2.2.15 cells, with an IC50 value of 8 nM. This reagent is valuable for research into antiviral therapies and the mechanisms of HBV infection. -
HBV CpAM
HBV-IN-18 is an HBV capsid assembly modulator (CpAM) that selectively targets the Hepatitis B virus capsid. It demonstrates a biological activity with an EC50 value of 2790 nM, indicating its potential in inhibiting viral assembly. This compound is applicable in research focused on understanding Hepatitis B virus biology and developing antiviral therapies. -
HBV Inhibitor
Oxynitidine is an HBV inhibitor that demonstrates potent activity against Hepatitis B virus DNA replication, with an ID50 of 30.8 µg/mL. This compound serves as a valuable tool for investigating viral infections and can be utilized in the development of therapeutic interventions targeting HBV. -
HBV/HDV Inhibitor
HBV/HDV-IN-3 is a dual inhibitor targeting Hepatitis B Virus (HBV) and Hepatitis D Virus (HDV), demonstrating an effective EC50 of less than 50 nM against HBV. This compound shows significant antiviral activity and is suitable for research applications focused on the development of therapeutics for HBV and HDV infections. Its effectiveness in inhibiting both viruses makes it a valuable tool for exploring antiviral strategies. -
HBV Inhibitor
AB-506 is an orally bioavailable inhibitor of hepatitis B virus (HBV) replication that targets the viral core protein. By binding to the HBV core protein, AB-506 facilitates capsid assembly and inhibits the encapsidation of HBV pgRNA. This compound is intended for use in research related to chronic hepatitis B (CHB) and provides a valuable tool for studies on viral replication mechanisms and potential therapeutic interventions. -
HBV Capsid Inhibitor
(S)-Canocapavir is an isomer of the antiviral agent Canocapavir, specifically targeting the HBV core protein. It functions as an HBV capsid inhibitor by binding to the hydrophobic pocket at the dimer-dimer interface of the HBV core protein (HBc). This binding promotes the intracellular accumulation of nonfunctional HBV capsids, thereby disrupting viral replication and interfering with the interaction between HBc and the HBV large surface protein. (S)-Canocapavir is relevant for research into hepatitis B virus (HBV) infection and its associated pathologies. -
HBV cccDNA Reducer
HBV-IN-25 is a potent HBV cccDNA reducer with demonstrated oral bioavailability. It exhibits anti-HBeAg potency and anti-HBV activity, with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 possesses excellent aqueous solubility (LYSA > 452 μg/mL) and favorable pharmacokinetic properties, with no observed cellular toxicity. This compound is suited for research applications focused on hepatitis B virus infection and its associated pathologies. -
Anti-HBV Drug
Sanggenol P is a flavonoid with demonstrated anti-hepatitis B virus (HBV) activity, specifically targeting HBV-infected HepG2.2.15 cell lines in vitro. This compound may serve as a valuable tool in the research of HBV-related therapies and the development of antiviral strategies. Its potential role in inhibiting HBV replication highlights its relevance for further studies in hepatology and virology. -
HBV Fragment
HBV Seq1 aa:18-27 is a peptide fragment derived from the hepatitis B virus (HBV) core antigen, specifically representing amino acids 18 to 27. This fragment is valuable for research applications focused on HBV immune response, vaccine development, and diagnostic assays. Its use in studies can aid in the understanding of HBV pathogenesis and potential therapeutic strategies. -
HBV/HDV Inhibitor
HBV/HDV-IN-4 hydrochloride is a dual inhibitor targeting both Hepatitis B virus (HBV) and Hepatitis D virus (HDV), demonstrating potent activity with an EC50 of less than 50 nM against HBV. This compound serves as a valuable tool for investigating therapeutic strategies in viral hepatitis research and offers potential for the development of antiviral agents against these challenging infections. -
HBV RNA Destabilizer
AB-452 is a dihydroquinolizinone (DHQ) analogue that functions as a potent HBV RNA destabilizer. It effectively inhibits PAPD5 and PAPD7 proteins in vitro and demonstrates significant in vivo efficacy in chronic HBV mouse models. This compound serves as a valuable tool for the study of hepatitis B virus pathology and therapeutic interventions. -
HBV Inhibitor
Apigenin-4'-α-L-rhamnoside is a potent inhibitor of Hepatitis B virus (HBV) primarily targeting the secretion of HBV surface antigen (HBsAg). This compound has demonstrated significant efficacy in reducing HBsAg levels in HepG2.2.15 cell lines. Its application in research facilitates the exploration of HBV pathogenesis and potential therapeutic strategies for hepatotropic viral infections. -
HBV-DNA Inhibitor
Oleana-2,12-dien-28-oic acid is a potent HBV-DNA inhibitor that also targets HBsAg and HBeAg. This compound demonstrates significant antiviral activity, making it a valuable tool for studying hepatitis B virus infections. It is suitable for research applications focused on the mechanisms of HBV replication and potential therapeutic interventions. -
HBV Inhibitor
(-)-Carbovir is a potent inhibitor of Hepatitis B virus (HBV) replication. It exhibits antiviral activity by specifically targeting and interfering with HBV polymerase, thereby disrupting viral nucleic acid synthesis. This compound is primarily used in research contexts focused on developing therapeutic strategies for HBV infections and understanding the mechanisms of viral resistance. -
HBV Inhibitor
Bentysrepinine is an orally active inhibitor of the hepatitis B virus (HBV) that exhibits potent antiviral activity. It demonstrates favorable pharmacokinetic properties, with notable bioavailability across different species, including rats, dogs, and monkeys, and shows no accumulation in monkeys after 90 days of administration. This compound is being investigated for its potential applications in antiviral therapies and hepatitis research. -
HBV
Daplusiran is a small interfering RNA (siRNA) designed to target and promote the degradation of hepatitis B virus (HBV) mRNAs. By inhibiting the replication of HBV, it serves as a vital tool in the development of therapeutic strategies for HBV-related diseases. Research applications include studies focused on liver disease and antiviral interventions. -
HBV Inhibitor
HBV-IN-6 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 value of 44 nM. This compound effectively interferes with viral replication, making it a valuable tool for research focused on HBV-related mechanisms and therapeutic strategies. Its efficacy underscores its potential application in developing effective treatments for HBV infections. -
HBV Inhibitor
Antiviral Agent 38 is a potent inhibitor of the hepatitis B virus (HBV). This compound demonstrates significant antiviral activity, making it a valuable tool for research on HBV infections and their associated pathologies. Its efficacy positions it as an important reagent for studying HBV biology and potential therapeutic interventions. -
HBV DNA Inhibitor
HBV-IN-38 is an HBV DNA inhibitor, exhibiting an effective concentration (EC50) of ≤100 nM. This compound is primarily utilized in research to investigate the mechanisms of hepatitis B virus (HBV) infections and to evaluate potential therapeutic interventions against HBV replication. -
HBV Inhibitor
Rolicyprine is a potent inhibitor of Hepatitis B Virus (HBV) that also exhibits neuroprotective activity. It has been shown to alleviate depressive symptoms and promote neuroregeneration, making it relevant for neuropsychiatric research. Additionally, Rolicyprine demonstrates potential in alleviating anxiety, indicating its applicability in studies related to mood disorders and HBV infections. -
HBV Inhibitor
Erythrocentaurin is a natural compound that acts as an inhibitor of the hepatitis B virus (HBV). It exhibits potent antiviral activity, making it a promising candidate for research focused on HBV treatment and management. This compound can be utilized in studies aimed at understanding the mechanisms of HBV replication and the development of novel therapeutic strategies. -
HIV/HBV Inhibitor
L-Fd4A is an adenine derivative that inhibits both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) with effective concentrations (EC50) of 1.5 μM and 1.7 μM, respectively. This compound demonstrates promising antiviral activity while exhibiting low cytotoxicity, making it suitable for research applications in studying HIV and HBV inhibition mechanisms. -
Anti-HBV Agent
Di-Val-L-dC is a prodrug of L-deoxycytidine that targets hepatitis B virus (HBV) with specificity and selectivity. It exhibits potent antiviral activity against HBV, making it a valuable tool for research in viral infections and antiviral drug development. This compound provides insights into mechanisms of HBV replication and potential therapeutic interventions. -
HBV Inhibitor
HBV-IN-37 is a selective inhibitor of Hepatitis B virus (HBV) with an EC50 value of 10 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for researching therapeutic strategies against HBV infection. HBV-IN-37 is useful in elucidating the mechanisms of HBV replication and can serve as a lead compound in the development of antiviral agents targeting HBV. -
HBV Inhibitor
Yhhu6669 is a potent inhibitor of Hepatitis B Virus (HBV), targeting HBV DNA replication. It functions by inducing the formation of DNA-free capsids, effectively reducing HBV levels. In preclinical studies using AAV/HBV-infected mouse models, Yhhu6669 demonstrated significant decreases in both HBV DNA and HBcAg. Additionally, it exhibits favorable pharmacokinetic properties, making it a valuable tool for research in HBV therapeutic development. -
HBV
Tomligisiran is a small interfering RNA (siRNA) designed to target hepatitis B virus (HBV) mRNAs, promoting their degradation and effectively inhibiting HBV replication. This reagent plays a significant role in research focused on antiviral strategies and therapeutic approaches for HBV infections. Its utility in silencing HBV-specific RNA makes it a valuable tool for studying the molecular mechanisms of viral replication and pathogenesis. -
HBV Inhibitor
HBV-IN-7 is a potent inhibitor of Hepatitis B Virus (HBV) with an EC50 of 7 nM. This compound effectively interferes with viral replication, making it a valuable tool for researching HBV pathogenesis and therapeutic interventions. Its strong antiviral activity supports applications in the development of treatments for chronic hepatitis B infections. -
HBV Inhibitor
HBV-IN-8 is a potent inhibitor of hepatitis B virus (HBV) with an effective concentration (EC50) of 287.9 nM. This compound offers significant antiviral activity, making it a valuable tool for research applications focused on HBV infection and treatment mechanisms. HBV-IN-8 is suitable for investigations into the efficacy of antiviral agents in the pursuit of therapeutic strategies against HBV-related diseases.
